Pharmacokinetic parameters of ceftriaxone after single intravenous and intramuscular administration in camels (Camelus Dromedarius)

Pharmacokinetics of ceftriaxone in freshwater crocodiles (Crocodylus siamensis) after intramuscular administration at two dosages

One of the major obstacles to the successful treatment of infectious disease in freshwater crocodile species is incorrect dosing of antibiotics. There are few reports on pharmacokinetics and dosage regimens of antimicrobial drugs in crocodiles. The purpose of the present study was to clarify the pharmacokinetic characteristics of ceftriaxone (CEF) in Siamese freshwater crocodiles (Crocodylus siamensis). Freshwater crocodiles, Crocodylus siamensis, in breeding farms were treated with a single intramuscular administration of CEF at two dosages, 12.5 and 25 mg/kg body weight (b.w.). Blood samples were collected at preassigned times up to 168 hr. The plasma concentrations of CEF were measured by a validated method through liquid chromatography tandem-mass spectrometry. CEF plasma concentrations were quantified up to 72 and 96 hr after low- and high-dose administration, respectively. The C_max values of CEF were 24.61 ± 5.15 µg/ml and 26.39 ± 2.81 µg/ml at dosages of 12.5 and 25 mg/kg b.w., respectively. The AUC_last values increased in a dose-dependent fashion. The half-life values were not statistically different between the groups (around 20 hr). The average binding percentage of CEF to plasma protein was 53.78 ± 2.11%. Based on the pharmacokinetic data, susceptibility break-point and the surrogate PK-PD index (T > MIC, 0.2 μg/ml), i.m. administration of CEF at a dose of 12.5 mg/kg b.w. might be appropriate for initiating treatment of susceptible bacterial infections in freshwater crocodiles.

Pharmacokinetics of ceftriaxone in Green sea turtles (Chelonia mydas) following intravenous and intramuscular administration at two dosages

Green sea turtles are widely distributed in tropical and subtropical waters. Adult green sea turtles face many threats, primarily from humans, including injuries from boat propellers, being caught in fishing nets, pollution, poaching, and infectious diseases. To the best of our knowledge, limited pharmacokinetic information to establish suitable therapeutic plans is available for green sea turtles. Therefore, the present study aimed to describe the pharmacokinetic characteristics of ceftriaxone (CEF) in green sea turtles, Chelonia mydas, following single intravenous and intramuscular administrations at two dosages of 10 and 25 mg/kg body weight (b.w.). Blood samples were collected at assigned times up to 96 hr. The plasma concentrations of CEF were measured by liquid chromatography tandem mass spectrometry. The concentrations of CEF in the plasma were quantified up to 24 and 48 hr after i.v. and i.m. administrations at dosages of 10 and 25 mg/kg b.w., respectively. The C_max values of CEF were 15.43 ± 3.71 μg/ml and 43.48 ± 4.29 μg/ml at dosages of 10 and 25 mg/kg, respectively. The AUC_last values increased in a dose-dependent fashion. The half-life values were 2.89 ± 0.41 hr and 5.96 ± 0.26 hr at dosages of 10 and 25 mg/kg b.w, respectively. The absolute i.m. bioavailability was 67% and 108%, and the binding percentage of CEF to plasma protein was ranged from 20% to 29% with an average of 24.6%. Based on the pharmacokinetic data, susceptibility break-point and PK-PD index (T > MIC, 0.2 μg/ml), i.m. administration of CEF at a dosage of 10 mg/kg b.w. might be appropriate for initiating treatment of susceptible bacterial infections in green sea turtles.

Plasma disposition of cefoperazone after single intravenous and intramuscular administrations in camels (Camelus dromedarius)

The plasma disposition of cefoperazone was investigated after intravenous (IV) and intramuscular (IM) administrations of 20 mg/kg as a single dose in six camels (Camelus dromedarius) in a crossover design. Blood plasma samples were analysed by high-performance liquid chromatography (HPLC). After IV administration, elimination half-life (t_1/2β), volume of distribution at steady state (V_dss), total body clearance (Cl_tot) and mean residence time (MRT) of cefoperazone were 1.95 h, 0.38 L/kg, 0.17 L/h/kg and 2.16 h, respectively. After IM administration of cefoperazone, peak plasma concentration (C_max) was 21.95 μg/mL and it was obtained at (t_max) 1.23 h. Absorption half-life (t_1/2ab), elimination half-life and mean absorption time were 0.45 h, 2.84 h and 2.07 h, respectively. The bioavailability of cefoperazone was 89.42%. The lack of local reaction or any other adverse effects and the very good bioavailability following IM administration indicate that cefoperazone might be a promising alternative treatment for a variety of infectious diseases in camels.

A potential camel reservoir for extended-spectrum β-lactamase-producing Escherichia coli causing human infection in Saudi Arabia

The prevalence of antimicrobial resistance is continuing to increase. Consequently, efficient approaches to identify sources of resistance are required. This study aimed to compare Escherichia coli isolates from the intestinal tract of camels with isolates from human urinary tract infections (UTIs) in Al Ahsa Province, Kingdom of Saudi Arabia (KSA), for antimicrobial resistance and identification of extended-spectrum β-lactamases (ESBLs). A microbiological study was conducted on 100 samples of cecal contents from camels and 100 urine samples from female UTI patients, to isolate and confirm E. coli using the VITEK 2 Automated System. Sensitivity patterns and identification of ESBLs were analyzed using the antimicrobial susceptibility test. Molecular techniques were used to detect E. coli drug-resistant clones. The presence rate of E. coli in camels was 26.0 % (n = 26/100), and in human samples, the rate of E. coli was 33.0 % (n = 33/100). ESBLs were reported for the first time in KSA, in 26.9 % (n = 5/26) of camel samples and 36.4 % (n = 8/33) of human samples. The multi-drug resistance (MDR) index was 0.13 and 0.17, for camels and humans, respectively. Escherichia coli drug-resistant O25b:H4-sequence type 131(ST131) clone was detected in two camel and two human isolates. This study demonstrates a high presence rate of ESBL-producing E. coli (ESBL-EC) in camels for the first time in KSA. Confirmation of MDR strains and E. coli ST131 clone in human and camel isolates suggests that camels could be a potential reservoir for resistant E. coli strains contributing to the increase in antimicrobial resistance in KSA.

Anaphylactoid reaction caused by sodium ceftriaxone in two horses experimentally infected by Borrelia burgdorferi

BACKGROUND

Lyme borreliosis is a disease transmitted by ticks to mammals, especially in horses and humans. Caused by a spirochete Borrelia burgdorferi, it can result in lameness, arthritis, carditis, dermatitis and neurological signs. Anaphylactoid reactions are severe responses caused by direct action of substances (drugs, toxins), which can pose risks to life. Still poorly documented in horses, these reactions are caused by the effects of inflammatory mediators such as histamine, kinins and arachidonic acid metabolites. The last two are the most clinically relevant for the species.

CASE PRESENTATION

The simultaneous occurrence of anaphylactoid reaction in two horses experimentally infected by Borrelia burgdorferi undergoing intravenous treatment with ceftriaxone sodium is reported. It was administered 4.7 × 10(8) spirochetes intradermal and subcutaneous applications in both horses to evaluate clinical aspects of the Lyme disease, 95 days before the application of sodium ceftriaxone. During the administration, one horse (a gelding) showed immediate and severe anaphylactoid symptoms such as urticaria, dyspnea, tachycardia, and eyelid edema, which were controlled by injecting dexamethasone. After 1 day, it expressed signs of abdominal discomfort, caused by severe bloat, which was treated surgically via celiotomy. Subsequently, this gelding had piroplasmosis and severe anemia, requiring treatment with an antimicrobial and blood transfusion. Second horse (a mare) showed signs of hypotension during the application of the antibiotic, which disappeared only when the application was interrupted. Days after the event, the mare developed moderate large colon bloat, which was treated with medication only. Subsequently the mare was evolved into the prodromal phase of laminitis in one of the forelimbs, which was treated for 10 days with non-steroidal anti-inflammatory and rheology modifying drugs and cryotherapy.

CONCLUSIONS

From the two cases presented here, it does appear that sodium ceftriaxone can induce anaphylactoid reactions in horses infected by Borrelia burgdorferi, which may evolve into colic syndrome, laminitis and the occurrence of opportunistic infections. However, further evidence should be collected in order to draw definite conclusions.

Disposition of ceftriaxone in hepatopathic goats following single-intramuscular dosing

Hepatopathy sometimes may interfere with metabolism and/or elimination of drugs which undergo major hepatic clearance. Twelve healthy goats were equally divided into two groups (I and II) and hepatopathy was induced by carbontetrachloride in the second group (group II). A single dose of ceftriaxone at 50 mg/kg was administered to each group intramuscularly. Disposition of ceftriaxone in plasma of healthy goats showed a typical absorption-reabsorption phase. However, the reabsorption phase was totally absent in hepatopathic goats and the disposition of ceftriaxone showed only absorption and distribution/elimination phase. The drug persisted in plasma for 6 h in hepatopathic animals, whereas the drug can only be detected up to 2 h in healthy animals indicating longer persistence of ceftriaxone in the former group. Ceftizoxime, the active metabolite of ceftriaxone was available in urine of group I animals, whereas only ceftriaxone was detected in the urine of hepatopathic animals suggesting impairment of metabolism of the parent drug in hepatopathy. Therefore, the reabsorption and metabolism of ceftriaxone in goats should be taken into consideration for drug monitoring.

In vitro and in vivo methods to measure the ceftriaxone distribution into the rat tail intervertebral disc

To characterize the pathway of ceftriaxone penetration into intervertebral discs, rat-tail discs were collected and immersed in a ceftriaxone solution for an in vitro study. For this in vivo experiment, plasma and tail discs were collected 30 min after ceftriaxone administration (463.2 mg/kg, equal to 500 mg/kg disodium salt, iv). The ceftriaxone levels in the plasma and discs were determined with HPLC by a reversed-phase C18 column and a mobile phase of methanol and a 10 mM K(2)HPO(4) solution (pH 6.7) (21:79, v/v). The results indicate that ceftriaxone was undetectable by the in vitro model. The concentrations of ceftriaxone in plasma and in intervertebral discs were 147.4 ± 21.2 and 4.0 ± 1.7 µg/mL (as disodium salt), respectively. Our results suggest that a sufficient blood supply is required for the passive diffusion of ceftriaxone into intervertebral discs. The concentration ratio of ceftriaxone in intervertebral disc-to-plasma was about 2.7% at 30 min after ceftriaxone disodium administration (500 mg/kg, iv).